Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fleming

Showing results (371-380 of 426) with videos related to

Pageof 43
Sort By:
Biorxiv : the Preprint Server for Biology|October 24, 2023
APOLLO: A genome-scale metabolic reconstruction resource of 247,092 diverse human microbes spanning multiple continents, age groups, and body sitesAlmut Heinken, Timothy Otto Hulshof, Bram Nap, et al.
Cell Systems|February 13, 2025
A genome-scale metabolic reconstruction resource of 247,092 diverse human microbes spanning multiple continents, age groups, and body sitesAlmut Heinken, Timothy Otto Hulshof, Bram Nap, et al.
European Urology|April 5, 2024
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 TrialSumanta K Pal, Petros Grivas, Shilpa Gupta, et al.
Nature Biotechnology|February 20, 2018
Recon3D enables a three-dimensional view of gene variation in human metabolismElizabeth Brunk, Swagatika Sahoo, Daniel C Zielinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
The Prostate|November 20, 2019
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 studyDaniel P Petrylak, Nicholas J Vogelzang, Kamal Chatta, et al.
Science Advances|January 18, 2023
Extensive field evidence for the release of HONO from the photolysis of nitrate aerosolsSimone T Andersen, Lucy J Carpenter, Chris Reed, et al.
Cancer|August 7, 2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancerTian Zhang, Michael R Harrison, Peter H O'Donnell, et al.
European Urology|December 18, 2017
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on OutcomesMatthew D Galsky, Huan Wang, Noah M Hahn, et al.
Urologic Oncology|September 13, 2015
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activityNoah M Hahn, Beatrice S Knudsen, Siamak Daneshmand, et al.
Pageof 43

Showing results (371-380 of 426) with videos related to

Sort By:
Pageof 43
Biorxiv : the Preprint Server for Biology|October 24, 2023
APOLLO: A genome-scale metabolic reconstruction resource of 247,092 diverse human microbes spanning multiple continents, age groups, and body sitesAlmut Heinken, Timothy Otto Hulshof, Bram Nap, et al.
Cell Systems|February 13, 2025
A genome-scale metabolic reconstruction resource of 247,092 diverse human microbes spanning multiple continents, age groups, and body sitesAlmut Heinken, Timothy Otto Hulshof, Bram Nap, et al.
European Urology|April 5, 2024
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 TrialSumanta K Pal, Petros Grivas, Shilpa Gupta, et al.
Nature Biotechnology|February 20, 2018
Recon3D enables a three-dimensional view of gene variation in human metabolismElizabeth Brunk, Swagatika Sahoo, Daniel C Zielinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
The Prostate|November 20, 2019
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 studyDaniel P Petrylak, Nicholas J Vogelzang, Kamal Chatta, et al.
Science Advances|January 18, 2023
Extensive field evidence for the release of HONO from the photolysis of nitrate aerosolsSimone T Andersen, Lucy J Carpenter, Chris Reed, et al.
Cancer|August 7, 2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancerTian Zhang, Michael R Harrison, Peter H O'Donnell, et al.
European Urology|December 18, 2017
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on OutcomesMatthew D Galsky, Huan Wang, Noah M Hahn, et al.
Urologic Oncology|September 13, 2015
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activityNoah M Hahn, Beatrice S Knudsen, Siamak Daneshmand, et al.
Pageof 43